Fibroblast growth factor-1 improves cardiac functional recovery and enhances cell survival after ischemia and reperfusion A fibroblast growth factor receptor, protein kinase c, and tyrosine kinase-dependent mechanism by Palmen, Meindert et al.
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ardiac Functional Recovery and Enhances
ell Survival After Ischemia and Reperfusion
Fibroblast Growth Factor Receptor,
rotein Kinase C, and Tyrosine Kinase-Dependent Mechanism
eindert Palmen, MD, PHD,* Mat J. A. P. Daemen, MD, PHD,† Leon J. De Windt, PHD,*
odil Willems,‡ Willem R. M. Dassen, PHD,* Sylvia Heeneman, PHD,† Rene Zimmermann, PHD,§
arc Van Bilsen, PHD,‡ Pieter A. Doevendans, MD, PHD¶
aastricht and Utrecht, the Netherlands; and Bad Nauheim, Germany
OBJECTIVES We sought to investigate the role of fibroblast growth factor (FGF)-1 during acute
myocardial ischemia and reperfusion.
BACKGROUND The FGFs display cardioprotective effects during ischemia and reperfusion.
METHODS We investigated FGF-1–induced cardioprotection during ischemia and reperfusion and the
intracellular signaling pathways responsible for these effects in an ex vivo murine setup of
myocardial ischemia and reperfusion.
RESULTS Cardiac-specific human FGF-1 overexpression was associated with enhanced post-ischemic
hemodynamic recovery and decreased lactate dehydrogenase release during reperfusion.
Inhibition of the FGF receptor, protein kinase C (PKC), and tyrosine kinase (TK) resulted
in blockade of FGF-1-induced protective effects on cardiac functional recovery and cell death.
CONCLUSIONS The overexpression of FGF-1 induces cardioprotection through a pathway that involves the
FGF receptor, PKC, and TK. (J Am Coll Cardiol 2004;44:1113–23) © 2004 by the
American College of Cardiology Foundations
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wibroblast growth factor-1 (FGF-1) or acidic FGF is a
ultifunctional peptide that belongs to the large family of
GFs. Fibroblast growth factor-1 is produced by a myriad
f cell types, including cardiomyocytes (1,2), endothelial
ells (1,2), macrophages (1), and fibroblasts (1). In the heart,
GF-1 and its most important receptor, FGF-R1, play a
ivotal role in the regulation of cardiac morphogenesis (3),
ngiogenesis (4), arteriogenesis (5), and cardiac remodeling
fter myocardial infarction (6). Recently, it was reported
hat FGFs mediate direct cardioprotective effects during
cute ischemia and reperfusion (I/R) by the induction of an
schemic preconditioning (IPC)-like state (7–9). Both the
dministration (10) and overexpression (11) of FGF-2 result
n cardioprotection. Furthermore, these studies demonstrated
hat FGF-2-mediated protection was dependent on mitogen-
ctivated protein kinases (MAPKs), tyrosine kinases (TKs),
nd protein kinase C (PKC) isoform activation.
Fibroblast growth factor-1 also is considered to be pro-
ective in ischemic heart disease. Pre-ischemic administra-
ion of FGF-1 decreases cardiomyocyte apoptosis rates after
schemia and reperfusion in vitro, thereby enhancing cell
urvival (7). Moreover, Htun et al. (8) showed that pretreat-
ent with FGF-1 induced a state of IPC in a porcine model
f regional myocardial ischemia. Finally, Buehler et al. (9)
From the Departments of *Cardiology, †Pathology, and ‡Physiology, Cardiovas-
ular Research Institute Maastricht (CARIM), Maastricht, the Netherlands; §Vas-
ular Genomics, Bad Nauheim, Germany; and Interuniversity Cardiology Institute
etherlands and ¶Heart Lung Center Utrecht (HLCU), Utrecht, the Netherlands.
Manuscript received December 12, 2002; revised manuscripts received March 1,e004, accepted May 4, 2004.howed that constitutive cardiac-specific FGF-1 overex-
ression delayed myocardial infarct formation in vivo.
Several intracellular mediators that are considered to play
pivotal role in IPC and cardioprotection have been
elineated. One of the crucial steps in IPC involves the
ctivation of distinct PKC isoforms, most notably, the
-isoform. Upon activation, PKC isoforms translocate to
istinct subcellular localizations, where they mediate their
rotective effects and initiate gene transcription. (12)
ence, PKC activation induces cardioprotection in several
nimal models (10,12–14), including the mouse (15–17). In
ddition to PKC isoforms, TK have been implicated in
PC-mediated protection. During IPC, the TK isoforms
rc and Lck become activated in a PKC-dependent fashion
13,18).
Although much is known about the pathways involved in
he long-term effects of FGF-1 on mitogenesis and protein
ynthesis, which are mediated through high-affinity binding
o the FGF-R1 receptor, very little is known about the
echanisms of growth factor-mediated cardioprotection
nd the intracellular signaling pathways involved. Whether
r not reported FGF-induced cardioprotective effects are
eceptor (FGF-R1) mediated or depend on interaction of
GFs with yet-unknown intracellular targets is still a point
f debate in literature. Although FGF-1 and -2 lack a leader
equence, which is necessary to exteriorize the protein,
GFs are released during the contraction of cardiac myo-
ytes, allowing a receptor-mediated mechanism (19). This
as demonstrated by Htun et al. (8), who showed thatxogenous FGF-1–mediated protection is receptor-mediated.
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FGF-1–Mediated Cardioprotection During I/R September 1, 2004:1113–23owever, several reports suggest that exogenous FGF-1
nd -2 are internalized by the formation of a complex with
GF-R1 (20), which might indicate the existence of an
ntracellular target for this growth factor complex.
In this study, we investigated the effects of constitutive
ardiac-specific human isoform of FGF-1 overexpression on
ardiac functional recovery and cell survival after acute,
lobal myocardial ischemia and reperfusion in an isolated,
orking mouse heart set-up. A marked cardioprotective
ffect of FGF-1 overexpression was demonstrated, which
ritically depended upon the activation of intracellular
ignaling pathways using FGF-R1 and the activation of
KC and TK.
ETHODS
dult, male transgenic (TG) mice with cardiac-specific
verexpression of the human isoform of FGF-1 were
escribed previously (5). We used the fourth and fifth
eneration of the TG founders. The transgene construct is
omposed of a cytomegalovirus enhancer, a 2.2-kb MLC-2v
romotor driving the 2.1-kb human FGF-1 cDNA, and is
ompleted by a SV40 polyadenylation site. This transgene
esulted in a two- to three-fold cardiac-specific FGF-1
verexpression, as confirmed by Northern, Western blotting
nd immunohistochemistry (Fig. 1) (5). All experiments
escribed in this study were approved by the Institutional
nimal Care and Use Committee at Maastricht University.
xperiments were performed by researchers who were
linded to treatment group and genotype.
erfusion system. All the chemicals used for the Krebs-
enseleit solution were of the highest grade available and
urchased from Merck (Darmstadt, Germany), except for
he D()-glucose and pyruvate (Sigma, St. Louis, Mis-
ouri) and the (human) insulin (Actrapid, Novo Nordisk
Abbreviations and Acronyms
AOF  aortic flow
DMSO  dimethyl sulfoxide
dP/dtmax  maximal rate of positive pressure
development (in mm Hg/s2)
dP/dtmin  minimal rate of negative pressure
development (in mm Hg2)
FGF  fibroblast growth factor
HW/BW  heart weight/body weight
IPC  ischemic preconditioning
I/R  ischemia and reperfusion
LDH  lactic dehydrogenase
LVDP  left ventricular developed pressure
LVEDP  left ventricular end diastolic pressure
LVPdia  diastolic left ventricular pressure
LVPsys  systolic left ventricular pressure
MAPK  mitogen-activated protein kinase
PKC  protein kinase C
TG  transgenic
TK  tyrosine kinase
WT  wild typearma B.V., Alphen a/d Rijn, the Netherlands). For this ctudy, a mouse heart perfusion system as described by de
indt et al (21,22) was used. This murine “assisted-mode”
solated heart model closely resembles the in vivo situation
n the mouse regarding both the generation of cardiac
utput and left ventricular pressure curves (21).
solated ejecting mouse heart preparation. Mice were
enotyped by polymerase chain reaction and anesthetized
ith pentobarbital (Nembutal, Sanofi Sante, Maassluis, the
etherlands, 50 mg/kg i.p.). After thoracotomy, the heart
as excised quickly and placed immediately in ice-chilled
erfusion buffer. The hearts were perfused with recirculat-
ng, prefiltered Krebs-Henseleit (KH) solution consisting of
in mM): NaCl 118, KCl 4.7, CaCl2 3.0, MgSO4 1.2,
H2PO4 1.2, NaHCO3 25, Na-EDTA 0.5, D()-glucose
0, and pyruvate 1.5, which was gassed with carbogen (95%
2, 5% CO2). In the presence of 0.5 mM ethylenediamine
etraacetic acid, nominal free [Ca2] was 2.5 mM. Insulin
evels in the perfusate were 0.15 U/l. PO2 pressure exceeded
50 mm Hg, and pH values ranged between 7.40 and 7.45.
he temperature of the heart was maintained at 38.5°C.
The native ascending aorta was connected to the aortic
annula, mounted in the perfusion system, and immediately
erfused retrogradely at a pressure of 50 mm Hg, after
hich the heart resumed spontaneous beating. A specially
esigned aortic cannula was used, matching the hemody-
amic impedance characteristics of the murine ascending
orta (21). Subsequently, a PE-50 catheter (Clay Adams,
arsippany, New Jersey) was introduced via the apex to
easure left ventricular pressure. The left atrium was
annulated through a pulmonary vein using a 20-G cannula
t a fixed preload of 10 mm Hg. Mean arterial pressure was
onitored just downstream from the aortic cannula by using
n identical pressure transducer. Finally, a water jacket
38.5°C) was placed around the heart to avoid temperature
uctuations. The hearts were paced at a frequency of 450
eats/min (except during ischemia).
emodynamic data acquisition. All hemodynamic pa-
ameters were recorded continuously using specialized soft-
are (Hemodynamic Data Acquisition System, Technical
epartment, Maastricht University) allowing online mea-
urement, calculation, and presentation of aortic flow
AOF), cardiac output, systolic left ventricular pressure
LVPsys), diastolic left ventricular pressure (LVPdia), left
entricular end diastolic pressure (LVEDP), mean arterial
ressure, and left ventricular maximal rate of positive
ressure development (dP/dtmax) and minimal rate of neg-
tive pressure development (dP/dtmin). Left ventricular de-
eloped pressure (LVDP) was defined as the difference
etween LVPsys and LVEDP. Cardiac output was defined
s the sum of AOF and coronary flow. Coronary flow was
etermined from the difference between left atrial filling
ow, as measured by the 2 N inline flow probe, and AOF,
s measured by the 1 N inline flow probe. Before each
xperiment, flow probes and pressure transducers were
alibrated.
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September 1, 2004:1113–23 FGF-1–Mediated Cardioprotection During I/Rxperimental protocol. After positioning the left atrial
nflow catheter and pacing electrodes, antegrade perfusion
nd online data acquisition were started, after which the
eart was allowed to stabilize for 20 min. In the last minute
f this period, coronary effluent was collected, and baseline
emodynamic measurements were calculated. Subsequently,
oth left atrial filling flow and the aortic outflow tract were
losed using an occluder, thereby initiating the no-flow
ormothermic ischemic period. In separate pilot experi-
ents, we investigated the optimal duration of the ischemic
eriod in three mice. The most pronounced effects on
ardiac function were observed after 25 min of ischemia,
nd this period was used in the subsequent experiments.
fter completion of normothermic ischemia, the aortic
lamp was released, allowing retrograde reperfusion of the
oronaries for 10 min. After reperfusion in the Langendorff
retrograde) mode, the left atrial inflow was reopened to
llow antegrade perfusion. After additional 60 min of
eperfusion, the heart was removed quickly from the system,
ash frozen, and stored at 80°C for further analysis.
oronary effluent was collected at 5, 10, 15, 25, 35, and 60
in of reperfusion and directly frozen in liquid nitrogen. To
tabilize lactate dehydrogenase (LDH) in the effluent,
ovine serum albumin solution was added to a final con-
entration of 3%.
iochemical analysis. Lactate and LDH concentrations
ere measured in the coronary effluent as markers of
naerobic metabolism and myocardial cell death. Lactate
nd LDH were assessed spectrometrically using a Cobas Bio
utoanalyzer (Roche, Gipf-Oberfrick, Switzerland) accord-
ng to the method of Apstein et al. (23) and Bergmeyer and
ernt et al. (24).
harmacological interventions. To obtain pharmacolog-
cal inhibition of several intracellular signaling peptides,
nhibitors (lavendustin A [LA], 0.5 M, Sigma, St.
ouis, Missouri; chelerythrine chloride [CHE], 5 M,
igma; and SU5402 [SU], 25 M, Calbiochem, Darm-
tadt, Germany) were dissolved in either dimethyl sul-
oxide (DMSO) or dH2O, according to the guidelines of
anufacturer, diluted in KH solution, and administered
t final doses known to be much greater than the IC50
alues to wild-type (WT) or TG littermates (n  6 per
roup).
Lavendustin A, a cell-permeable general inhibitor of
ytoplasmic TKs, was dissolved in 0.01% DMSO (10).
helerythrine chloride (5 M) was used to inhibit PKC and
as dissolved in dH2O. SU5402 (25 M) was dissolved in
MSO (0.01%) (10). SU5402 selectively inhibits the intra-
ellular kinase of the FGF-R1, thereby preventing receptor
imerization (8,25).
Baseline hemodynamic values were obtained after 15 min
f stabilization. Subsequently, the system was switched from
he ejecting mode to the Langendorff mode for drug
dministration to reduce the amounts of inhibitor used and
o prevent the inhibitor from entering the perfusing system.
he inhibitors were administered during 10 min via an Mortic cannula side hole, located 3 mm above its entrance. A
erfusor pump was used to assure constant inhibitor levels.
he inhibitor/KH solution was concentrated eight times to
imit perfusion with unsaturated buffer. After completion of
rug delivery, the heart was subjected to 25 min of ischemia,
ollowed by 60 min of reperfusion. Coronary effluent was
ampled after hemodynamic stabilization, during drug de-
ivery, and during the reperfusion phase. The remaining part
f the protocol was executed as described before.
Pilot experiments (n  3 for both WT and TG)
emonstrated that switching from ejecting mode to Lange-
dorff mode and back again did not influence cardiac
unction or cardiac functional recovery. Because certain
nhibitors were dissolved in DMSO (0.01%), we tested
hether either inhibitor or DMSO alone influenced cardiac
unction (n  3, data not shown), and no effect was
emonstrated.
mmunoblotting and immunoprecipitation. Ventricular
issue samples (subjected to I/R) were powdered with a
ortar and pestle and further homogenized at 4°C in a
uffer containing 0.5% Triton, 0.5% NP-40, 10 mM Tris
pH 7.5), 2.5 mM KCI, 150 mM NaCl, 20 mM
-glycerolphosphate, 50 mM NaF, 1 mM orthovanadate,
0 g/ml leupeptin, 1 mM dithiothreitol, 10 g/ml
oytrypsin inhibitor, and 200 mM benzamine using a
olytron tissue homogenizer (Kinematica AG, Littau,
witzerland), and centrifuged for 20 min at 7,000 g.
amples containing equal amounts of protein (20 to 40
g) were separated by sodium dodecyl sulfate-
olyacrylamide gel electrophoresis (8% to 12%) and
estern blotting was performed as described previously
26). Antibodies and other supplies were obtained from
he following sources: polyclonal PKC- antibody was
rom Upstate Biotechnology (Lake Placid, New York);
nd New England Biolabs (Beverly, Massachusetts) sup-
lied polyclonal anti-phosphospecific antibodies against
xtracellular responsive kinase (ERK)1/2, c-Jun NH2-
erminal kinase (JNK)1/2, and p38 and polyclonal
RK1/2, JNK, and p38 antibodies. Data were quantified
y assessment of the integrated optical density.
To detect PKC translocation, separate cytosolic and
articulate fractions were prepared from ventricular tissue
27). Briefly, tissue samples were homogenized in 25 mM
ris-Cl, pH 7.5; 4 mM ethylenebis(oxyethylenenitrilo)-
etraacetic acid, 2 mM ethylenediamine tetraacetic acid, 5
M dithiothreitol, 1 mM phenylmethylsulfonyl fluoride,
nd 1 g/ml leupeptin and incubated on ice for 30 min.
fterwards, samples were spun at 100,000 g for 30 min
4°C). The supernatant was used as cytosolic fraction,
hereas the remaining pellet was rehomogenized with the
ame lysis buffer, now containing 1% Triton X-100, and
ncubated on ice for 30 min. After spinning the samples for
0 min at 100,000 g, the supernatant was saved as the
articulate fraction.
To investigate the effects of genotype and inhibitors on
APK activation and PKC translocation during ischemia
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FGF-1–Mediated Cardioprotection During I/R September 1, 2004:1113–23lone, three animals per group underwent 25 min of
schemia, omitting reperfusion. After the ischemic period
ad been completed, hearts were flash-frozen and tissue
amples were prepared as described above, followed by
estern blotting and densitometry.
tatistics. The results are presented as means SEM. The
ffect of genotype was evaluated using the Mann-Whitney
test or Kruskall-Wallis test, depending on the number of
roups to be compared. The influence of time and genotype
nd their interactions on hemodynamic parameters and
nzyme release was assessed using a two-way analysis of
ariance. A level of p  0.05 was considered to be of
tatistical significance.
ESULTS
eneral. The average body weight was similar in both
roups (WT [n  36]; 29.6  0.8 g, FGF [n  39]; 28.3
0.9 g, p  NS), as were heart weights and heart
eight/body weight (HW/BW) ratios (WT: HW  153 
0 mg, HW/BW 5.3 0.3 103; FGF: HW 151
mg, HW/BW  5.1  0.4  103, p  NS). To correct
or differences in the site of genomic incorporation and copy
umber of the transgene construct, we investigated two
istinct founder lines (lines 1 and 2), both of which carried
he same transgene construct. No differences between both
ines were found in HW and HW/BW ratios, basal cardiac
unction, or response to I/R or to inhibitor compounds.
ecause effects were similar in both lines, the experiments
or this study were performed only in the line 1 animals.
re-ischemic hemodynamics. No differences were ob-
erved in pre-ischemic, intrinsic heart rates between both
enotypes (TG vs. WT) and amounted to 380 beats/min.
emodynamic parameters did not change during the 15-
in stabilization, indicating a stable baseline hemodynamic
ituation. No hemodynamic differences were observed be-
ween both genotype groups, indicating an equal pre-
schemic hemodynamic situation (Table 1).
ibroblast growth factor-1 protects cardiac functional
ecovery and improves cell survival after ischemia and
eperfusion. After an ischemic period of 25 min, cardiac
unction deteriorated in both transgenic mice and non-
ransgenic litter mates. In WT mice, AOF decreased
ramatically from 10.0  1.2 ml/min antegrade to only
igure 1. Left ventricular tissue of fibroblast growth factor-1 (FGF-1) tran
Promega, Madison, Wisconsin), and Vector red was applied as the seconda
bserved in FGF-1 transgenic mice. Negative control shows background s
evel of FGF-1 in the non-transgenic littermates.etrograde flow (114%), indicating severe systolic dysfunc- oion, whereas in FGF transgenic hearts, recovery of AOF
as partially preserved (a 44% decrease from 9.7 ml/min to
.2 ml/min, antegrade flow, p 0.001) (Fig. 2A). Similarly,
VPsys (73%) and LVDP (91%) (Fig. 2B) decreased to
ery low values in WT hearts, whereas in TG hearts, only a
odest decrease was observed (11% decrease for LVPsys
data not shown] and 22% decrease in LVDP, p  0.001).
n addition, LV dP/dtmax (Fig. 2C) and dP/dtmin values
ecreased dramatically in WT mice (90% and 87%,
espectively), whereas in TG mice, only a minor decrease
as observed (15% and 7%, respectively, p  0.001
ompared with WT). In addition, post-ischemic diastolic
unction was largely preserved in TG hearts compared with
heir WT counterparts. In WT mice, LVPdia increased
ix-fold after I/R, indicating severe diastolic dysfunction,
hereas in TG mice, near-complete preservation of LVPdia
28%, p  0.001 compared with WT) was observed (Fig.
D). No differences in LVEDP were found between both
enotypes (data not shown). No differences between both
enotypes were found for coronary flow values for each of
he different time points measured, indicating that coronary
ow was not increased as the result of FGF-1.
Baseline, pre-ischemic LDH values were similar in both
xperimental groups (WT: 27.1  6.8 U/l·min vs. FGF-1:
1.5  6.1 U/l·min; p  NS). Induction of global cardiac
schemia resulted in increased LDH release in both genotypes
uring the first 5 min of reperfusion (78.5  23.7 U/l·min vs.
2.812.8 U/l·min, p  0.05, compared with baseline) In
T mice, LDH release further increased (maximum of
.2-fold) and remained elevated throughout the 60 min of
eperfusion, indicating ongoing myocardial cell damage. In
ontrast, in the FGF-1 group, LDH release quickly dropped to
aseline levels after an initial washout peak and remained at
aseline levels throughout the remainder of the reperfusion
eriod (Fig. 3A).
Pre-ischemic lactate release was equal in both experimen-
al groups (WT: 836  169 mol/l·min vs. FGF: 798 
50 mol/l·min; p  NS, Table 1). After ischemia, a
ashout peak for lactate was observed in both groups during
he first minutes of reperfusion (WT: 1,297  190 mol/
·min vs. FGF: 1,535  175 mol/l·min), after which
actate release returned to baseline values. No significant
ifferences were observed between both genotypes through-
c and wild-type mice was stained with polyclonal antibody against FGF-1
tibody. The diffuse staining of cardiomyocytes and extracellular matrix was
g with only the secondary antibody Vector red. Note the low expressionsgeni
ry an
taininut the protocol (Fig. 3B).
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September 1, 2004:1113–23 FGF-1–Mediated Cardioprotection During I/Rnraveling the signaling pathways involved in FGF-1–
ediated cardiac protection. Cardiac-specific FGF-1
verexpression results in a marked cardioprotective effect on
oth functional recovery and cell survival after global myo-
ardial ischemia and reperfusion. Our next goal was to assess
he relative activation status of various intracellular signaling
athways that may underlie this phenomenon.
In TG control hearts not subjected to I/R (WT and
G, n  3), both phosphorylated and nonphosphory-
ated ERK-1/2 were increased, resulting in a normal
hospho-ERK/ERK ratio (Fig. 4A). In addition, in TG
ontrol hearts, PKC- translocation to the particulate
raction was constitutively enhanced. No differences in
38 and JNK phosphorylation were found between WT
nd TG control groups (Figs. 4C and 4D). No differences
ere found in amount of the nonphosphorylated isoform
f each of the MAPKs in all experimental groups (data
ot shown).
Because the differences in cardiac functional recovery
ere already apparent directly after initiation of reperfusion,
e decided to perform a separate experiment in which WT
nd TG hearts were subjected to 25 min of ischemia alone
nd investigated the effects on MAPK and PKC activation.
wenty-five minutes of ischemia resulted in enhanced
hosphorylation levels of all three MAPKs (ERK-1/2,
NK-1/2, p38). Compared with WT hearts, FGF-1 TG
earts showed higher phospho-ERK/ERK ratios (Fig. 4B).
o differences were found for JNK (Fig. 3C) and p38 (Fig.
D) activation between both genotypes after induction of
schemia. In addition, PKC- translocation to the particu-
ate fraction was enhanced after ischemia in both experi-
ental groups. The level of PKC- translocation in WT
earts increased to the preischemic level of TG (Fig. 4A).
his was associated with a decrease in cytosolic PKC-.
When hearts were subjected to 60 min of reperfusion,
fter the ischemic stimulus, the genotype-dependent differ-
nces in ERK-activation and PKC translocation completely
isappeared (data not shown).
K activation underlies FGF-1–mediated cardioprotection.
o intrinsic effects of the agents or DMSO (0.01%) were
ound on cardiac function and LDH/lactate release, which
ere tested during 85 min of antegrade perfusion. No
ignificant differences were found between experimental
roups for both pre-ischemic systolic (AOF, LVPsys,
VDP, LV dP/dtmax) and diastolic (LVPdia, LVEDP, and
V dP/dtmin) function (Figs. 5A to 5D). Ischemia resulted
n a dramatic decrease in both systolic and diastolic cardiac
unction in WT animals, similar to the non-treated WT
nimals (data not shown). The administration of LA did
ot influence WT parameters (data not shown) but com-
letely blocked the hemodynamic protective effects of
GF-1 in TG animals, whereas post-ischemic LDH release
as comparable with non-treated TG hearts. This indicated
hat the cardioprotective effect of FGF-1 on functional
ecovery, but not necrosis, was dependent on TK activity(Fig. 6). Finally, the addition of LA reduced the activationT W F W F W F W F L 
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FGF-1–Mediated Cardioprotection During I/R September 1, 2004:1113–23f ERK (expressed as phospho-ERK-1/2/ERK-1/2 ratios)
n FGF transgenic hearts to the level of untreated WT
ontrols (Fig. 4B), indicating that attenuation of cardiopro-
ection in FGF hearts may be accompanied by a decreased
ctivation of pERK in these hearts. Treatment with LA also
educed pJNK activation (Fig. 4C), although no differences
igure 2. Cardiac function and cardiac functional recovery after global isc
ontrol hearts: (A) Aortic flow in ml/min. (B) Left ventricular developed pr
n mm Hg/s2). (D) Left ventricular diastolic pressure (in mm Hg). *p  0.
angendorff reperfusion, and “15, 25, 35, 60 min” indicate 15, 25ere observed between both genotypes. Surprisingly, the cdministration of LA resulted in a marked upregulation of
38 activation in both genotypes (Fig. 4D).
harmacologic inhibition of PKC results in partial
brogation of FGF-1–induced protection. Compared
ith the non-treated FGF-1 group, the CHE-treated group
FGF/CHE) showed a moderate but significant decrease in
a and reperfusion in fibroblast growth factor (FGF) and wild-type (WT)
in mm Hg. (C) Maximal rate of positive pressure development (dP/dtmax
mpared with WT. “Basal” indicates the pre-ischemic period, “L” indicates
and 60 min of antegrade reperfusion, respectively.hemi
essure
05 co
, 35,ardiac functional recovery after ischemia and reperfusion,
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September 1, 2004:1113–23 FGF-1–Mediated Cardioprotection During I/Rndicating partial abrogation of the FGF-1–induced cardiopro-
ective effect (Figs. 5A to 5D). Similarly, CHE pretreatment in
GF-1 transgenic hearts resulted in an increased LDH release
fter I/R compared with non-treated FGF-1 TG and de-
reased PKC translocation to the particulate fraction (Fig. 4A).
nduction of ischemia resulted in decreased cytosolic levels of
KC- in all experimental groups (data not shown).
nhibition of FGF-R1 attenuates FGF-1–induced pro-
ection. SU5402 did not affect cardiac functional recovery
igure 3. Pre- and post-ischemic lactate dehydrogenase (LDH) (A) and
actate (B) release in fibroblast growth factor (FGF) and wild-type (WT)
ontrol hearts (lactate in mol/l·min and LDH in U/l; *p 0.05 compared
ith WT). “Basal” indicates the pre-ischemic period, “L” indicates Lan-
endorff reperfusion, and “15,25,35,60 min.” indicates 15, 25, 35,
nd 60 min of antegrade reperfusion, respectively.n WT hearts (data not shown). When administered to pGF-1 hearts, SU completely abrogated the FGF-1–
nduced protection of cardiac functional recovery that was
bserved in the non-treated FGF-1 group (Figs. 5A to 5D).
s in treatment with LA, LDH release in SU-treated FGF
G hearts remained low after I/R and comparable with
ntreated FGF TG despite decreased cardiac functional
ecovery, indicating that FGF-R1 blockade did not prevent
GF-1–mediated protection of cell survival (Fig. 6).
ISCUSSION
n a murine ex vivo working heart model of ischemia and
eperfusion, we found marked cardioprotective effects of
ardiac-specific FGF-1 overexpression on cardiac functional
ecovery and cell survival. The protective effects on cardiac
unctional recovery are dependent on the activation of
GF-R1, PKC, and TK, as pharmacologic inhibition of
hese signaling peptides abolished the cardioprotective effect
f FGF-1. The FGF-1–mediated protection of cell viability
as partially dependent on PKC and completely indepen-
ent of FGF-R1 and TK. To our knowledge, this is the first
eport directly linking FGF-1–mediated cardiac protection
o a known IPC pathway.
Several groups have observed beneficial effects of FGF-1
uring acute myocardial ischemia. Buehler et al. (9) dem-
nstrated in an in vivo model of regional myocardial I/R
hat FGF-1 overexpression results in delayed infarct forma-
ion when compared with WT counterparts. This effect
roved to be only temporary because the same infarct size
as eventually reached, indicating a trophic effect of FGF-1
ather than cardioprotection due to increased collateral flow
nd limitation of infarct size. This is in agreement with data
rom our group, demonstrating that coronary artery ligation
n these FGF-1 transgenic mice does not result in attenu-
tion of infarct size one week after permanent coronary
rtery ligation (6). The trophic effects of FGF-1 were
reviously reported by Htun et al. (8), who demonstrated
hat the administration of FGF-1 to pigs before myocardial
schemia mimicked a state of ischemic preconditioning (8).
ntracellular signaling pathways involved in FGF-
ediated protection. Several mechanistic studies have
een conducted, mainly focusing on the denomination of
he signaling pathways involved in FGF-2–mediated pro-
ection. In these studies, strong involvement of TK and
KC was demonstrated. Previously, Padua et al. (10)
howed in an ex vivo rat heart model of global myocardial
/R that pretreatment with FGF-2 improved cardiac func-
ional recovery in a PKC- and TK-dependent manner.
ecently, Sheikh et al. (11) elegantly demonstrated that
GF-2 overexpression increased cardiomyocyte viability in
n ex vivo cardiac ischemia and reperfusion model. FGF-2
verexpression was associated with constitutively enhanced
hosphorylation levels of p38 and pJNK, in addition to
nhanced expression of PKC- and -. Surprisingly, no
ffects on cardiac functional recovery after I/R were re-
orted, whereas exogenous FGF-2 administration did result
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FGF-1–Mediated Cardioprotection During I/R September 1, 2004:1113–23igure 4. Western blot analysis demonstrating the activation of mitogen-activated protein kinases (MAPKs) (ERK-1/2, JNK-1/2, p38) and protein kinase
(PKC)- translocation to the particulate fraction. Each lane was loaded with equal amounts of protein. Polyclonal antibodies were used to detect bands.
he upper panel of each figure is a representative blot, whereas the lower panels depict grouped densitometric data (mean  SEM) from three
xperiments. For MAPKs, we used the ratio of phosphorylated MAPK/non-phosphorylated MAPK. (A) The upper panel shows a representative blot of
he amount of PKC- translocation to the particulate fraction, whereas the lower panel demonstrates the quantitative densitometric data of PKC-
ranslocation to the particulate fraction. (B to D) The upper panels show a representative blot of the activated form of each MAPK subtype, whereas the
ower panel depicts the quantification of densitometric data. (B) phospho-ERK, (C) phospho-JNK1/2, (D) phospho-p38. CHE  chelerythrine; FGF 
broblast growth factor transgenic littermates; IR ischemia and reperfusion; LA lavendustin A; PKC protein kinase C; WT wild-type littermates.
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September 1, 2004:1113–23 FGF-1–Mediated Cardioprotection During I/Rn moderately enhanced functional recovery. In addition,
ogoyevitch et al. (28) demonstrated PKC-, -, and -
pregulation after FGF-1 administration to isolated cardiac
yocytes.
We and others showed in different models that the
igure 5. Cardiac functional recovery in untreated fibroblast growth factor
he hemodynamic effects of pretreatment of FGF hearts with selective
FGF/SU). (A) Aortic flow. (B) Left ventricular developed pressure. (C) M
entricular diastolic pressure. *p  0.05 compared with WT, †p  0.05 co
U5402. “Basal” indicates the preischemic period, “L” indicates Langendor
f antegrade reperfusion, respectively.rotective effects of FGF-1 and -2 (10) can be abrogated by pelective PKC inhibition. Although this indicates that PKC
s required for FGF-1-mediated cardioprotection, it does
ot necessarily imply that PKC translocation is depending
n activation of the FGF-R1. It merely suggests that PKC
ranslocation is a prerequisite and indispensable for the
) and wild-type (WT) control hearts. In addition, this figure demonstrates
itors of tyrosine kinases (FGF/LA), PKC (FGF/CHE), and FGF-R1
al rate of positive pressure development (dP/dtmax in mm Hg/s
2). (D) Left
ed with FGF. Che  chelerythrine chloride; LA  lavendustin A; SU 
rfusion, and “15, 25, 35, 60 min” indicates 15, 25, 35, and 60 min(FGF
inhib
axim
mpar
ff repereconditioning phenomenon to occur.
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FGF-1–Mediated Cardioprotection During I/R September 1, 2004:1113–23There is some evidence that FGF-1-induced protection is
ediated by TK, as is FGF-2–mediated protection (10).
tun et al. (8) showed that FGF-1 administration and its
inding to FGF-R1 induces TK activation. We demon-
trated that FGF-1–induced protection of cardiac func-
ional recovery could be completely abrogated by the ad-
inistration of LA, indicating that TK activation is
ecessary for FGF-1–induced cardioprotection. However,
he FGF-1–induced protection of cell viability during I/R is
ot dependent on TK because the inhibition of TK did not
ffect LDH release in TG hearts, which could be accounted
or by species-dependent differences in TK-mediated cell
eath.
We demonstrate that administration of SU, an FGF-R1
locker, resulted in complete abrogation of protection of
unction. This is in agreement with Htun et al. (8), who
uggested that FGF-1–induced protection was receptor
ediated. Surprisingly, the protective effects of FGF-1 on
ell survival could not be inhibited by FGF-R1 blockade,
ndicating that prevention of I/R-induced cell death is, at
east partially, dependent on intracellular FGF-1.
ffects of FGF-1 on cardiac cell survival during ischemia
nd reperfusion. In the FGF-1 group, LDH release dur-
ng reperfusion was attenuated when compared with WT
nimals. However, as already shown previously (21), this
elease accounts for only 8% of the total LDH content of
he heart. Therefore, in this model, only a minor part of the
otal cardiomyocyte population becomes necrotic due to
schemia. The relatively small reduction in necrosis due to
GF-1 overexpression may therefore not explain the large
ifference in cardiac functional recovery that was observed
etween both genotypes. Interestingly, inhibition of PKC
ranslocation, but not inhibition of FGF-R1 and TK
ctivation, enhanced cell death in TG animals, suggesting
igure 6. Pre- and post-ischemic lactate dehydrogenase (LDH) release in
on-treated and inhibitor-treated fibroblast growth factor (FGF) hearts
nd wild-type (WT) control hearts. LDH release in U/l (*p  0.05
ompared with WT, †p  0.05 compared with FGF). CHE  cheleryth-
ine; LA  lavendustin A; SU  SU5402. Open bars  pre-ischemia;
losed bars  post-ischemia.hat FGF-1–dependent protection on cell survival after I/R ss partially dependent on PKC, but completely independent
f FGF-R1 and TK.
Fibroblast growth factor-1 is known to decrease apoptosis in
n in vitro model of hypoxia and reoxygenation (7). However,
t seems unlikely that delayed activation of programmed cell
eath is the mechanism underlying the protective effects on cell
amage and function that we observed because the protective
ffects of FGF-1 became apparent immediately after starting
eperfusion and completion of the sequential activation of the
ascade involved in the process of apoptosis would take longer
han 25 min. In addition, we performed a terminal deoxynu-
leotidyl transferase-mediated deoxyuridine triphosphate-
igoxigenin nick end labeling assay on FGF-1 TG and WT
earts (data not shown), which showed no signs of apoptosis
fter 60 min of reperfusion. However, Dumont et al. (29)
howed annexin-V labeling early after initiation of reperfusion
n an in vivo murine model of myocardial I/R. Therefore, we
annot completely rule out the occurrence of early stages of
poptosis in this model.
Because myocyte necrosis or apoptosis cannot account for
he large functional differences in cardiac functional recov-
ry due to FGF-1 overexpression, we hypothesized that
GF-1 attenuates myocardial stunning, a process occurring
n the reperfused heart, in which certain areas of the heart
hat were previously ischemic are still viable but not con-
racting (30). Several groups demonstrated that stunning
ould be prevented by IPC (31,32). Furthermore, Htun
t al. (8) demonstrated that FGF-1 induces a state that
imics IPC. The fact that TK and FGF-R1 inhibition did
ot attenuate the FGF-1–mediated protection of cell sur-
ival further underlines this hypothesis.
ffects of FGF-1 on anaerobic metabolism. In our
odel, we observed a lactate washout peak 5 min after the
tart of reperfusion, indicating anaerobic glycolysis during
he ischemic phase. Lactate release returned to baseline
ithin 10 min after the start of reperfusion. This indicates
hat after 10 min, little anaerobic metabolism is present in
he reperfused heart and that the myocardium is adequately
erfused in both genotypes. One might hypothesize that
actate release would remain elevated longer in the WT
roup when compared with FGF-1 animals because FGF-1
cts as a vasodilator (33), facilitating the reopening of
oronary arterioles and capillaries. However, both at base-
ine and throughout the rest of the experimental protocol,
o differences in lactate release between both genotype
roups could be observed. In addition, no effects on lactate
elease could be observed in inhibitor-treated WT and TG
earts.
ossible implications for future growth factor therapy. In
he majority of both animal and human studies, FGF-1 and
2 overexpression or exogenous administration were dem-
nstrated to be beneficial for the heart in situations of acute
schemia (7,8). The results of this study suggest that
re-ischemic FGF-1 administration might protect the heart
rom subsequent ischemic damage. In addition, one could
peculate that administration of FGF-1 to cardioplegia
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September 1, 2004:1113–23 FGF-1–Mediated Cardioprotection During I/Rolutions during cardiac surgery might further reduce isch-
mia and reperfusion-induced damage.
One of the limitations of this model is that FGF-1 is
resent before the ischemic period is commenced, which
oes not resemble the human situation of reperfusion
uring myocardial infarction. Additional studies are re-
uired to investigate whether FGF-1 also protects cardiac
unction and reduces reperfusion damage when adminis-
ered only during restoration of flow. If this hypothesis
ould be confirmed, new treatment options are within reach.
ne of these is to administer FGF-1 simultaneously with
hrombolytic therapy in patients suffering from acute myo-
ardial infarction, with the purpose of reducing infarct size
nd improving cardiac functional recovery.
onclusions. Cardiac-specific FGF-1 overexpression re-
ults in augmentation of cardiac functional recovery and
ttenuation of reperfusion-induced myocardial cell necrosis
uring I/R. The protective effects attributed to FGF-1 were
inked to a known IPC pathway by demonstrating that
rotection is dependent on FGF-R1, PKC, and TK. These
ndings might have important implications for future
rowth factor therapy and for the prevention of reperfusion-
nduced damage.
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